Rimegepant for migraine: acute efficacy beyond the USA
-
Published:2023-06
Issue:6
Volume:22
Page:456-457
-
ISSN:1474-4422
-
Container-title:The Lancet Neurology
-
language:en
-
Short-container-title:The Lancet Neurology
Author:
Mitsikostas Dimos D
Subject
Neurology (clinical)
Reference10 articles.
1. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine;Lipton;N Engl J Med,2019
2. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial;Croop;Lancet,2019
3. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial;Croop;Lancet,2021
4. Patients' preferences for headache acute and preventive treatment;Mitsikostas;J Headache Pain,2017
5. Targeting calcitonin gene-related peptide: a new era in migraine therapy;Charles;Lancet,2019